Table 2. Characterisation of tumour infiltrating lymphocytes (TIL) in five NPC patients.
| TIL (N=5)a | NPC (%) |
|---|---|
| CD4+CD25+ | 32.24±7.59%b |
| CD4+CD25+Foxp3+ | 30.96±7.18b |
| CD4+CD25+Foxp3+CCR7− | 86.42±8.79c |
| CD4+CD25high | 12.37±2.45%b |
| CD4+CD25highFoxp3+ | 10.96±1.09b |
| CD4+CD25highFoxp3+CCR7− | 84.98±11.79d |
a
Four patients were from the group of 56 with PB Treg data and one was also analysed for T-cell proliferation suppression assay, but with no PB Treg data.
b
% in TIL.
c
% in CD4+CD25+ Treg.
d
% in CD4+CD25high Treg.